Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clinton’s Drug Plan Embraces CER-Driven Pricing ‘Accountability’

This article was originally published in The Pink Sheet Daily

Executive Summary

Think tank report that informed the plan suggests impact of CER reviews could be bolstered by use of NIH "march-in" rights if prices stay "unreasonably" high despite review conclusions.


Related Content

Ahead Of Speech, Democrats Skeptical About Trump Drug Pricing Plans
Dems' 'Better Deal' Would Create Drug Price Gouging 'Enforcer'
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Clinton Transition Team Includes Tanden, Underscoring Rx Pricing Focus
NIH Resists “March In” On Norvir Patents Based On Pricing Concerns


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts